Global Neurotrophic Keratitis Treatment Market 2018-2022

The global neurotrophic keratitis treatment market is predicted to reach a size of more than USD 614 million by 2022 with the increasing adoption of rhNGF as a therapy for the neurodegeneration of the central and peripheral nervous system. Wondering how to make the most of this booming neurotrophic keratitis treatment industry? Technavio’s extensive industry research report offers a detailed insight that will allow you to take full advantage of the opportunities available to you. This study provides an in-depth analysis of the market by considering the evolving demographics and consumer behavior in the global neurotrophic keratitis treatment market. It also examines the competitive landscape and some leading neurotrophic keratitis therapy vendors that include Allergan, Bausch Health, and Bayer.

Want to get a preview about how you can gain compelling insights from Technavio’s market research report? Check out the latest facts about the neurotrophic keratitis treatment industry

The global neurotrophic keratitis treatment market is expected to grow at a CAGR of more than 4% during the forecast period

Neurotrophic keratitis treatment industry growth is expected to accelerate over the next five years, driven by growing geriatric population which will boost the demand for various types of keratopathy treatment. The Americas will drive around 39% of the growth for the global neurotrophic keratitis treatment market, while EMEA and APAC are also predicted to contribute significantly to the incremental growth in the forecast period. The common treatment options for neurotrophic keratitis include prophylaxis and surgery. Neurotrophic keratitis is related to the alterations in the corneal nerves which results in impairment of sensory and trophic functions with a consequent breakdown of the corneal epithelium. Technavio’s neurotrophic keratitis treatment industry analysis reveals promising markets around the world.

Want a bigger picture? Get a free sample of this report now!

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.

TA dominated the neurotrophic keratitis treatment market by product type

The global neurotrophic keratitis treatment market was dominated by TA product segment with a market share of over 42%, followed by rhNGF and others. TA treatment method is likely to remain dominant in the global neurotrophic keratitis treatment market over the forecast period, while rhNGF and others product segments are forecasted to witness a decline in market share over the next five years. In addition, factors such as advances in technology and rising aged population with affected vision are expected to boost the demand for neurotrophic keratitis treatment over the next few years.

Get more value with Technavio’s subscription platform! Gain easy access to all Technavio’s reports, along with on-demand services. Start your 14-day FREE trial

Allergan, Bausch Health, and Bayer are among the leading neurotrophic keratitis treatment companies

The global neurotrophic keratitis treatment market is forecasted to grow increasingly concentrated with the existence of a few international and regional vendors who offer keratopathy treatment for neurotrophic keratitis. Most of the established manufacturers in the global neurotrophic keratitis treatment market are focused on evaluation of various phases of drug development for corneal anesthesia and keratopathy treatment for neurotrophic keratitis. Many international and regional vendors are vying for their share of the market, and players must differentiate themselves to gain vital traction over their peers.

This report offers a complete analysis of several companies, including:

• Allergan
• Bausch Health
• Bayer
• Dompé farmaceutici
• Novartis

Want to dial in on a specific region or segment? We can help! Our analysts can customize this report to meet your requirements. Get in touch